FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

Search

Syncona Ltd

Fermé

102 3.55

Résumé

Variation du prix de l'action

24h

Actuel

Min

98.3

Max

102

Chiffres clés

By Trading Economics

Revenu

-68M

Ventes

44M

Marge bénéficiaire

-153.576

Employés

1,215

EBITDA

-49M

Dividendes

By Dow Jones

Prochains Résultats

13 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

602M

Ouverture précédente

98.45

Clôture précédente

102

Syncona Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 oct. 2025, 23:50 UTC

Actions en Tendance

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct. 2025, 23:25 UTC

Résultats

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct. 2025, 23:18 UTC

Résultats

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct. 2025, 22:20 UTC

Résultats

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct. 2025, 22:13 UTC

Résultats

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct. 2025, 21:38 UTC

Résultats

Correction to Visa Sales Jump Article

28 oct. 2025, 21:17 UTC

Résultats

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct. 2025, 21:07 UTC

Résultats

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct. 2025, 21:02 UTC

Résultats

Mondelez Tempers Outlook as Costs Rise

28 oct. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct. 2025, 23:02 UTC

Résultats

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct. 2025, 23:01 UTC

Résultats

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct. 2025, 22:46 UTC

Résultats

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct. 2025, 22:45 UTC

Résultats

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct. 2025, 22:44 UTC

Résultats

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct. 2025, 22:43 UTC

Résultats

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct. 2025, 22:42 UTC

Résultats

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct. 2025, 22:40 UTC

Résultats

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct. 2025, 22:40 UTC

Résultats

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct. 2025, 22:20 UTC

Résultats

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct. 2025, 22:02 UTC

Résultats

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct. 2025, 21:42 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

28 oct. 2025, 21:42 UTC

Market Talk
Résultats

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct. 2025, 21:20 UTC

Résultats

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct. 2025, 21:19 UTC

Résultats

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct. 2025, 21:18 UTC

Résultats

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparaison

Variation de prix

Syncona Ltd prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat